HLD-0915 for metastatic prostate cancer that has worsened after earlier treatments
Tests HLD-0915 in adults with metastatic prostate cancer that progressed after earlier treatments.
Key facts
- Who runs it
- Janssen Research & Development, LLC
- Where
- Austin, Boston, Colorado Springs, Denver, Durham, Grand Rapids, Houston, Long Island City, Metairie, Myrtle Beach, Nashville, New Haven, Norfolk, Omaha, Sarasota, and Syracuse, United StatesSee the 17 sitesAlso in 1 other country, 1 site
- Trial code
- Registry title
- Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 190 people, planned
- Started
- 6 Feb 2025
- Expected to end
- 17 Aug 2028
- Type of study
- Interventional, 7 groups
- Treatments tested
- JNJ-101556143 Formulation 1
- JNJ-101556143 Formulation 2
- JNJ-101556143 Formulation 3
- Record updated
- 3 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with metastatic prostate cancer. Some groups have cancer that grew despite earlier treatment. Others have hormone-sensitive disease.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Prostate adenocarcinoma confirmed by tissue or cell tests, spread to other parts of the body (metastatic). Some groups: castration-resistant disease with PSA rising on the last treatment. Other groups: hormone-sensitive disease with distant spread seen on standard imaging.
- Earlier treatment
- Castration-resistant groups: earlier orchiectomy or ongoing androgen-deprivation therapy, with castrate testosterone level. One hormone-sensitive group: treated with a next generation ARPI for at least 180 days and up to 365 days, with no progression, and no earlier chemotherapy for prostate cancer.
- Biomarker or test result
- Castration-resistant groups: castrate level of serum testosterone and PSA progression on the last regimen. One hormone-sensitive group: PSA ≥0.2 ng/mL. Other hormone-sensitive groups: PSA >2.0 ng/mL and serum testosterone >150ng/ml.
Main reasons for not taking part
- A recent major bleed or a known bleeding disorder
- Tumour with a neuroendocrine or small cell carcinoma component
- Continuous corticosteroids above 10 mg/day prednisone-equivalent
- Cancer treatment or investigational drugs within 2 weeks before the first dose (castration-resistant groups)
- Cancer only in the pelvic lymph nodes (some hormone-sensitive groups)
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- All Study Arms (Phase 1 Part 1 \& 2, Phase 2 Part 1, Part 2A, 2B, 2C \& 2D):
- Males ≥ 18 years old Histological, pathological, and/or cytological confirmation of prostate adenocarcinoma Adequate hematological, renal, and hepatic function. Able to swallow oral medication
- mCRPC Arms: (Phase 1 Part 1 \& 2, Phase 2 Part 1): Prior orchiectomy or ongoing androgen-deprivation therapy and a castrate level of serum testosterone Progressive mCRPC defined as having demonstrated PSA progression on the prior regimen
- SOAR Arm (Phase 2 Part 2A) mHSPC with distant metastatic disease based on conventional imaging PSA ≥0.2 ng/mL, following treatment with next generation ARPI for at least 180 days and up to 365 days No evidence of radiographic or PSA progression while receiving ARPI
- mHSPC arms (Phase 2 Part 2B, 2C \& 2D) serum testosterone >150ng/ml mHSPC with distant metastatic disease based on conventional imaging and PSA >2.0 ng/mL
Who cannot take part
- Has experienced a recent major bleed or has a known bleeding disorder Tumors exhibiting neuroendocrine or small cell carcinoma component by histopathology Receiving continuous corticosteroids at prednisone-equivalent dose of >10 mg/day Prior or ongoing significant medical condition
- mCRPC arms: (Phase 1 Part 1 \& 2, Phase 2 Part 1): Has received systemic anti-cancer therapy or investigational drugs within 2 weeks prior to first dose of study drug with certain exceptions requiring longer washout periods
- SOAR arm (Phase 2 Part 2A) Has received any prior cytotoxic chemotherapy for prostate cancer
- mHSPC arms (Phase 2 Part 2B, 2C \& 2D) regional pelvic lymph node disease only
- All arms (Phase 1 Part 1 \& 2, Phase 2 Part 1, Part 2A, 2B, 2C \& 2D):
Other criteria
- Patients must meet the following criteria to be eligible study participation:
Where in United States
Also in 1 other country, 1 site
- NEXT OncologyAustin, United StatesTaking people
- Dana Farber/Mass General Brigham Cancer Care, IncBoston, United StatesTaking people
- Rocky Mountain Cancer CenterColorado Springs, United StatesTaking people
- Sarah Cannon Research Institute 1Denver, United StatesTaking people
- Duke University Medical CenterDurham, United StatesTaking people
- South Texas Accelerated Research Therapeutics, LLC (START)Grand Rapids, United StatesTaking people
- MD Anderson Cancer CenterHouston, United StatesTaking people
- Memorial Sloan Kettering Cancer CenterLong Island City, United StatesTaking people
- XCancer Research Network LCMC Health EJGHMetairie, United StatesTaking people
- Carolina Urologic Research CenterMyrtle Beach, United StatesTaking people
- Sarah Cannon Research InstituteNashville, United StatesTaking people
- Urology AssociatesNashville, United StatesTaking people
- Yale UniversityNew Haven, United StatesTaking people
- Virginia Clinical ResearchNorfolk, United StatesTaking people
- Urology Cancer Center PCOmaha, United StatesTaking people
- Florida Cancer SpecialistsSarasota, United StatesTaking people
- Associated Medical ProfessionalsSyracuse, United StatesTaking people
About the trial
What the trial wants to find out
Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.
The 7 groups in the trial
- JNJ-101556143 Phase 1 Part 1 - Dose EscalationTreatment being tested
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)
Treatment: JNJ-101556143 Formulation 1
- JNJ-101556143 Phase 1 Part 2 - Formulation ExplorationTreatment being tested
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)
Treatment: JNJ-101556143 Formulation 1, JNJ-101556143 Formulation 2, and JNJ-101556143 Formulation 3
- JNJ-101556143 Phase 2 Part 1 - Dose OptimizationTreatment being tested
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)
Treatment: JNJ-101556143 Formulation 1
- Phase 2 Part 2A - SOARTreatment being tested
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)
Treatment: JNJ-101556143 Formulation 1
- Phase 2 Part 2B - HSPC ExpansionTreatment being tested
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)
Treatment: JNJ-101556143 Formulation 1
- Phase 2 Part 2C - HSPC ExpansionTreatment being tested
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)
Treatment: JNJ-101556143 Formulation 1
- Phase 2 Part 2D - HSPC ExpansionTreatment being tested
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)
Treatment: JNJ-101556143 Formulation 1
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Phase 1/2 Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
- Plain-language title
- HLD-0915 for metastatic prostate cancer that has worsened after earlier treatmentsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 3 November 2026